Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Decoy Therapeutics Inc.SLRX · Entity 937 | Director · Chief Executive Officer | April 11, 2024 | April 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Decoy Therapeutics Inc.
Report date April 11, 2024 · Filed April 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2034-04-11 | Direct | 20,500 |
Reported balance
After 2024-04-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-11 · Grant · Acquired 20,500 · Balance 20,500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 11, 2024 Filed Apr 12, 2024 20:50 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001615219-24-000034 · wk-form4_1712955014.xml · derivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2034-04-11 Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:04 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 14,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000023 · wf-form4_167649503732734.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,019 F1 · shares: Restricted stock granted under the Salarius Pharmaceuticals, Inc. 2015 Equity Incentive Plan in lieu of cash for performance bonus. The shares of common stock are subject to a six-month holding period pursuant to the terms of the restricted stock agreement. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:33 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000002 · wf-form4_167295795521891.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,719 F1 · kind: Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 25% of the shares of restricted stock will vest on January 2, 2024, and 1/36 of the remaining shares of restricted stock will vest on monthly anniversary thereafter. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 21:34 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 10,000 | $1.73 | $17,340.00 |
DisclosureSEC source: 0001615219-22-000142 · wf-form4_166785687791752.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,674 F1 · kind: These shares were acquired under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 03, 2022 Filed Nov 8, 2022 22:42 UTC Amendment | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 10,000 | $1.73 | $17,340.00 |
DisclosureSEC source: 0001615219-22-000144 · wf-form4a_166794733755240.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,026 F1 · kind: These shares were acquired under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c) Read SEC document |
| November 03, 2022 Filed Dec 12, 2022 23:34 UTC Amendment | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 2,693 | $1.73 | $4,669.66 |
DisclosureSEC source: 0001615219-22-000155 · wf-form4a_167088805437684.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,719 F1 · shares: The Reporting Person's previous Form 4 filed on November 7, 2022 and amended on November 8, 2022 incorrectly reported the Reporting Person acquiring 10,000 shares of common stock under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c), when it should have been reported as 2,693 shares of common stock. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:17 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 10,800 | $0.18 | $1,990.44 |
DisclosureSEC source: 0001615219-22-000087 · wf-form4_165403182105530.xml · nonDerivative · entry 5 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 303,574 F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:17 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 10,392 | $0.18 | $1,869.52 |
DisclosureSEC source: 0001615219-22-000087 · wf-form4_165403182105530.xml · nonDerivative · entry 4 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 292,774 F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:17 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 708 | $0.18 | $127.44 |
DisclosureSEC source: 0001615219-22-000087 · wf-form4_165403182105530.xml · nonDerivative · entry 3 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 282,382 F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:17 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 18,600 | $0.18 | $3,385.20 |
DisclosureSEC source: 0001615219-22-000087 · wf-form4_165403182105530.xml · nonDerivative · entry 2 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,674 Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:17 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 3,400 | $0.18 | $612.00 |
DisclosureSEC source: 0001615219-22-000087 · wf-form4_165403182105530.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,074 Read SEC document |
| May 03, 2022 Filed May 5, 2022 20:06 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 10,000 | $0.19 | $1,863.00 |
DisclosureSEC source: 0001615219-22-000069 · wf-form4_165178116032585.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,674 F1 · kind: The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 03, 2022 Filed Mar 9, 2022 21:01 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 139,488 | $0.39 | $54,539.81 |
DisclosureSEC source: 0001615219-22-000018 · wf-form4_164685969931166.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,674 F1 · shares: The Registrant issued these shares to the reporting person as part of his bonus; which shares were issued in lieu of net cash compensation. The shares were issued at the fair market value of the Registrants common stock on the date of grant. Read SEC document |
| January 20, 2022 Filed Jan 21, 2022 21:08 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001615219-22-000008 · wf-form4_164279927781443.xml · derivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2032-01-19 F1 · derivative.exercise_date: 25% of the options are fully vested on January 19, 2023, and 1/36 of the remaining options vest on each monthly anniversary thereafter. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 18:58 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 7,939 | $0.72 | $5,700.20 |
DisclosureSEC source: 0001615219-21-000096 · wf-form4_163613866819461.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,186 F1 · kind: The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuantto the issuer's Employee Stock Purchase Plan. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 20:08 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 2,000 | $0.89 | $1,784.00 |
DisclosureSEC source: 0001615219-21-000087 · wf-form4_162923091089935.xml · nonDerivative · entry 2 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 102,247 F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 20:08 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 2,000 | $0.90 | $1,798.00 |
DisclosureSEC source: 0001615219-21-000087 · wf-form4_162923091089935.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 100,247 F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:10 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 9,822 | $0.57 | $5,569.07 |
DisclosureSEC source: 0001615219-21-000040 · wf-form4_162024898808755.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,247 F1 · kind: The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 22:05 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001615219-20-000122 · wf-form4_160711949187470.xml · derivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2030-12-01 F1 · derivative.exercise_date: 25% of the options are fully vested on December 1, 2021, and 1/36 of the remaining options vest on each monthly anniversary thereafter. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 22:44 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 4,879 | $0.56 | $2,737.12 |
DisclosureSEC source: 0001615219-20-000106 · wf-form4_160461622928134.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,425 F1 · kind: The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 11:59 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 1,000 | $1.01 | $1,010.00 |
DisclosureSEC source: 0001615219-20-000095 · wf-form4_159792476762012.xml · nonDerivative · entry 2 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 2,000 Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 11:59 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 1,000 | $1.01 | $1,010.00 |
DisclosureSEC source: 0001615219-20-000095 · wf-form4_159792476762012.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 1,000 Read SEC document |
| July 14, 2020 Filed Jul 17, 2020 00:56 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 339,584 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001615219-20-000081 · wf-form4_159494738307174.xml · derivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,584 Underlying: Common Stock · 339,584 shares Expires 2030-07-13 F1 · derivative.exercise_date: 25% of the options are fully vested on July 14, 2021, and 1/36 of the remaining options vest on each monthly anniversary thereafter. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 22:02 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001615219-20-000025 · wf-form4_158517372311926.xml · derivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-22 F1 · derivative.exercise_date: 25% of the options granted are fully vested on March 23, 2021, and quarterly vesting of the remaining options over 3 years. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 02:32 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 2,175 | $1.15 | $2,501.25 |
DisclosureSEC source: 0000899243-20-004413 · doc4.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,546 Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 02:07 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseWarrants (right to buy) · Derivative | 2,175 | $0.01 Strike: $1.15 | $21.75 |
DisclosureSEC source: 0000899243-20-004567 · doc4.xml · derivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,175 Underlying: Common Stock · 2,175 shares Expires 2025-02-11 F1 · security: The Reporting Person acquired these securities in the Issuer's public offering of Class A Units on February 11, 2020. Each Class A Unit consisted of one share of Common Stock and one warrant to purchase a single share of Common Stock. Read SEC document |
| September 10, 2019 Filed Sep 13, 2019 10:16 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001615219-19-000039 · wf-form4_156836979901866.xml · derivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-09-10 F1 · derivative.exercise_date: The grant has a 4-year vesting schedule with 25% vesting on September 30, 2020 and 1/12th of the balance vesting on the last day of each calendar quarter thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.